Literature DB >> 34312518

Treat-to-target in axial spondyloarthritis - what about physical function and activity?

Jürgen Braun1, Xenofon Baraliakos2, Uta Kiltz2.   

Abstract

In patients with axial spondyloarthritis (axSpA), pain, functional and structural impairments, reduced mobility and potential deformity of the axial skeleton are the most prominent health concerns. Limitations in physical function and spinal mobility are caused by both inflammation and structural damage, and therefore restrictions to physical function must be monitored throughout a patient's life. Consequently, the assessment of physical function is recommended as a key domain in the Assessment of Spondyloarthritis International Society-OMERACT Core Outcome Set. However, in comparison with disease activity, physical function seems to be a relatively neglected target of intervention in patients with axSpA, even though physical function is a major contributor to costs and disability in this disease. This Review aims to reacquaint rheumatologists with the targets for physical function, physical activity and performance by giving guidance on determinants of physical function and how physical function can be examined in patients with axSpA.
© 2021. Springer Nature Limited.

Entities:  

Year:  2021        PMID: 34312518     DOI: 10.1038/s41584-021-00656-5

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  109 in total

Review 1.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

Authors:  Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2017-01-13       Impact factor: 19.103

2.  Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Authors:  Anne Boel; Anna Molto; Désirée van der Heijde; Adrian Ciurea; Maxime Dougados; Lianne S Gensler; Maria-José Santos; Eugenio De Miguel; Denis Poddubnyy; Martin Rudwaleit; Astrid van Tubergen; Floris A van Gaalen; Sofia Ramiro
Journal:  Ann Rheum Dis       Date:  2019-07-30       Impact factor: 19.103

3.  Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.

Authors:  Pedro Machado; Robert Landewé; Jürgen Braun; Kay-Geert A Hermann; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-24       Impact factor: 19.103

Review 4.  Axial spondyloarthritis.

Authors:  Joachim Sieper; Denis Poddubnyy
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

5.  Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.

Authors:  Denis Poddubnyy; Aleksandra Fedorova; Joachim Listing; Hildrun Haibel; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper
Journal:  J Rheumatol       Date:  2016-11-01       Impact factor: 4.666

6.  Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.

Authors:  Sofia Ramiro; Désirée van der Heijde; Astrid van Tubergen; Carmen Stolwijk; Maxime Dougados; Filip van den Bosch; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2014-05-07       Impact factor: 19.103

Review 7.  Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis.

Authors:  U Kiltz; D van der Heijde
Journal:  Clin Exp Rheumatol       Date:  2009 Jul-Aug       Impact factor: 4.473

Review 8.  Ankylosing spondylitis.

Authors:  Jürgen Braun; Joachim Sieper
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

9.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Authors:  M Rudwaleit; J Listing; J Brandt; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

10.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Authors:  Josef S Smolen; Monika Schöls; Jürgen Braun; Maxime Dougados; Oliver FitzGerald; Dafna D Gladman; Arthur Kavanaugh; Robert Landewé; Philip Mease; Joachim Sieper; Tanja Stamm; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Neil Betteridge; Filip van den Bosch; Laura C Coates; Paul Emery; Lianne S Gensler; Laure Gossec; Philip Helliwell; Merryn Jongkees; Tore K Kvien; Robert D Inman; Iain B McInnes; Mara Maccarone; Pedro M Machado; Anna Molto; Alexis Ogdie; Denis Poddubnyy; Christopher Ritchlin; Martin Rudwaleit; Adrian Tanew; Bing Thio; Douglas Veale; Kurt de Vlam; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

View more
  1 in total

Review 1.  The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis.

Authors:  Helena Marzo-Ortega; Victoria Navarro-Compán; Servet Akar; Uta Kiltz; Zoë Clark; Elena Nikiphorou
Journal:  Clin Rheumatol       Date:  2022-06-28       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.